Immunotherapy and Immune Disorders

Immunotherapy is one of the preventive treatment method employed against allergy and other immune disorders like asthma, rhinitis, cancer etc. The method involves several types depending on the causes and action for example either the method can prompt the immune system or just provide components and support the immune system. It can be activated, suppressed, helminthic, subcutaneous, sublingual and adjuvant immunotherapy. Disorders caused by the deficiency, failure or aberrant action of immune system or the malignant tumour growth in the immune system are immune disorders. They are several type’s namely immunodeficiency disorders (primary and secondary), Allergies and Autoimmune diseases. They are caused by agents like Foods, Latex, Medications, Allergens, Genetics, Pathogenic infections, Stress, Environmental factors and Toxins interacting with proteins.

The global cancer immunotherapy market is expected to reach USD 119.39 Billion by 2021 from USD 61.9 Billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market. In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region. On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021. The high growth in this segment is primarily attributed to the high success rate of these inhibitors.